We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Hollis-Eden Pharmaceuticals has initiated the first in a series of Phase I safety
and pharmacokinetic (PK) clinical trials with Neumune (HE2100), its investigational
immune regulating hormone for the treatment of acute radiation syndrome.
The FDA has approved Pfizer's depo-subQ provera 104 (medroxyprogesterone acetate
injectable suspension) for the management of pain associated with endometriosis,
a condition that occurs in women of reproductive age when excess endometrial
tissue of the uterus is present in other areas of the body, most commonly on
the ovaries or fallopian tubes.
Serono and Syntonix Pharmaceuticals have entered into an agreement under which
Serono has licensed worldwide exclusive rights to Syntonix's Transceptor and
Synfusion technologies for the development and commercialization of interferon-beta:Fc
products.
Metabasis Therapeutics has announced that, while it is continuing to evaluate
the implications of the serious adverse events as announced on March 16, the
company has been informed that a Phase I clinical trial of CS-917 is continuing
and that one or more additional Phase I clinical trials may be initiated soon
to further evaluate the product candidate.
Endo Pharmaceuticals has released clinical trial data that found patients receiving
either Lidoderm or Celebrex 200 mg for pain associated with osteoarthritis (OA)
of the knee experienced improvement in average daily pain intensity.
Rigel Pharmaceuticals has completed a Phase I clinical study of R406, an orally
delivered product candidate for the treatment of rheumatoid arthritis (RA),
a chronic inflammatory disease that progressively destroys joint cartilage and
bone.